SG10201913945QA - Taxane particles and their use - Google Patents

Taxane particles and their use

Info

Publication number
SG10201913945QA
SG10201913945QA SG10201913945QA SG10201913945QA SG10201913945QA SG 10201913945Q A SG10201913945Q A SG 10201913945QA SG 10201913945Q A SG10201913945Q A SG 10201913945QA SG 10201913945Q A SG10201913945Q A SG 10201913945QA SG 10201913945Q A SG10201913945Q A SG 10201913945QA
Authority
SG
Singapore
Prior art keywords
taxane particles
taxane
particles
Prior art date
Application number
SG10201913945QA
Other languages
English (en)
Inventor
Michael Baltezor
Joseph Farthing
Jake Sittenauer
Jahna Espinosa
Samuel Campbell
Matthew Mcclorey
Julia Fischer
Mark Williams
Gary Clapp
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of SG10201913945QA publication Critical patent/SG10201913945QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D46/00—Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D46/00—Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B01D46/24—Particle separators, e.g. dust precipitators, using rigid hollow filter bodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
    • B01J19/10—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/26—Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/02—Feed or outlet devices therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J4/00—Feed or outlet devices; Feed or outlet control devices
    • B01J4/001—Feed or outlet devices as such, e.g. feeding tubes
    • B01J4/002—Nozzle-type elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B05B1/3489—Nozzles having concentric outlets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B13/00—Machines or plants for applying liquids or other fluent materials to surfaces of objects or other work by spraying, not covered by groups B05B1/00 - B05B11/00
    • B05B13/02—Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work
    • B05B13/0278—Arrangement or mounting of spray heads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2271/00—Sealings for filters specially adapted for separating dispersed particles from gases or vapours
    • B01D2271/02—Gaskets, sealings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2204/00—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices
    • B01J2204/002—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices the feeding side being of particular interest
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2401/00—Form of the coating product, e.g. solution, water dispersion, powders or the like
    • B05D2401/90—Form of the coating product, e.g. solution, water dispersion, powders or the like at least one component of the composition being in supercritical state or close to supercritical state
SG10201913945QA 2015-06-04 2016-06-06 Taxane particles and their use SG10201913945QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171060P 2015-06-04 2015-06-04
US201562171001P 2015-06-04 2015-06-04
US201562171008P 2015-06-04 2015-06-04

Publications (1)

Publication Number Publication Date
SG10201913945QA true SG10201913945QA (en) 2020-03-30

Family

ID=56194575

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913947RA SG10201913947RA (en) 2015-06-04 2016-06-06 Taxane particles and their use
SG10201913945QA SG10201913945QA (en) 2015-06-04 2016-06-06 Taxane particles and their use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913947RA SG10201913947RA (en) 2015-06-04 2016-06-06 Taxane particles and their use

Country Status (14)

Country Link
US (11) US9814685B2 (fr)
EP (4) EP3302423B1 (fr)
JP (5) JP6921759B2 (fr)
KR (5) KR102077518B1 (fr)
CN (4) CN107743418A (fr)
AU (3) AU2016270558B2 (fr)
CA (3) CA3026452C (fr)
DK (1) DK3302431T3 (fr)
ES (1) ES2833749T3 (fr)
HK (3) HK1253020A1 (fr)
PT (1) PT3302431T (fr)
RU (1) RU2750163C2 (fr)
SG (2) SG10201913947RA (fr)
WO (3) WO2016197101A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102077518B1 (ko) 2015-06-04 2020-02-14 크리티테크, 인크. 노즐 어셈블리 및 사용 방법
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
EP3854381A1 (fr) 2016-04-04 2021-07-28 Crititech, Inc. Formulations pour le traitement de tumeurs solides
WO2017194145A1 (fr) * 2016-05-12 2017-11-16 Hewlett-Packard Development Company, L.P. Récipient pour matériau de construction
WO2018170210A1 (fr) 2017-03-15 2018-09-20 Dfb Soria, Llc Thérapie topique pour le traitement de la néoplasie intraépithéliale vulvaire (vin) et des verrues génitales à l'aide de nanoparticules de taxanes
WO2018170207A1 (fr) 2017-03-15 2018-09-20 Dfb Soria, Llc Thérapie topique pour le traitement de kératoses cutanées à l'aide de nanoparticules de taxanes
CA3056395C (fr) * 2017-03-15 2022-06-28 Dfb Soria, Llc Therapie topique pour le traitement de malignites cutanees au moyen de nanoparticules de taxanes
CN110730679A (zh) 2017-06-09 2020-01-24 克里蒂泰克公司 囊内注射抗肿瘤颗粒治疗上皮囊肿
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック，インコーポレイテッド 肺障害の治療方法
WO2019010316A1 (fr) * 2017-07-07 2019-01-10 Dfb Pharmaceuticals, Llc Traitement de croissances des tissus hyperplasiques comprenant une hyperplasie bénigne de la prostate (hbp) par injection directe d'un agent antinéoplasique
WO2019067851A1 (fr) 2017-09-29 2019-04-04 Crititech, Inc. Polymorphe de ciprofloxacine et son utilisation
EP3687500A1 (fr) 2017-09-29 2020-08-05 Crititech, Inc. Particules de glucocorticoïdes et leur utilisation
SG11202001802YA (en) * 2017-10-03 2020-03-30 Crititech Inc Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2019136188A1 (fr) * 2018-01-05 2019-07-11 Crititech, Inc. Traitement du cancer de la vessie par injection intratumorale de particules de taxane
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
US20190365699A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Treatment of Kidney Tumors by Intratumoral Injection of Taxane Particles
WO2019231499A1 (fr) 2018-05-31 2019-12-05 Crititech, Inc. Utilisation d'agents antinéoplasiques pour stimuler le système immunitaire pour le traitement du cancer
CN112243372A (zh) 2018-05-31 2021-01-19 克里蒂泰克公司 从受试者分离肿瘤特异性免疫细胞用于过继性细胞疗法的方法和癌症疫苗
CN108970835B (zh) * 2018-09-20 2020-11-17 马鞍山纽泽科技服务有限公司 一种耐高温喷射装置
WO2020072090A1 (fr) 2018-10-03 2020-04-09 Crititech, Inc. Utilisation d'agents antinéoplasiques pour stimuler le système immunitaire pour la production de structures lymphoïdes tertiaires (tls)
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
EP4099999A4 (fr) * 2020-02-04 2023-07-12 Zhuhai Beihai Biotech Co., Ltd. Formulations de docétaxel
US20220023215A1 (en) 2020-07-23 2022-01-27 Crititech, Inc. Lapatinib particles and uses thereof
KR20230044422A (ko) * 2020-07-23 2023-04-04 크리티테크, 인크. 소라페닙 입자 및 이의 용도
CN113447635B (zh) * 2021-05-11 2023-09-29 江西农业大学 一种盆栽类土壤不同深度温室气体释放速率测定装置
US11738029B2 (en) 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
US11738014B2 (en) 2021-11-10 2023-08-29 Crititech, Inc. Niraparib particles and uses thereof
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3648698A (en) * 1969-05-23 1972-03-14 George O Doherty Surgical collection unit
DE3120047C2 (de) * 1981-05-20 1984-03-29 Sterimed Gesellschaft für medizinischen Bedarf mbH, 6600 Saarbrücken Sauggerät zum Ansaugen von Körpersekreten
JPS5958019U (ja) 1982-10-08 1984-04-16 松下電器産業株式会社 電気集塵機
US4780138A (en) * 1986-10-27 1988-10-25 Bodine Albert G Sonic apparatus and method for facilitating the extraction of minerals from ore in a leachant
US5143528A (en) * 1990-02-14 1992-09-01 Challenge Industries Lint collector
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5409833A (en) * 1993-07-01 1995-04-25 Baxter International Inc. Microvessel cell isolation apparatus
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5480540A (en) 1994-10-17 1996-01-02 General Electric Company Spray apparatus for separating solids from fluids
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
WO1998029110A2 (fr) 1996-12-30 1998-07-09 Battelle Memorial Institute Preparation et methode de traitement de neoplasmes par inhalation
HU230338B1 (hu) 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JPH11189403A (ja) * 1997-12-25 1999-07-13 Tic:Kk 層構造型複合粒子製造装置
JP3418751B2 (ja) 1998-01-22 2003-06-23 参天製薬株式会社 フルオロメトロン懸濁型点眼剤
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
AU1556800A (en) 1998-11-25 2000-06-13 Universitatsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CA2371836C (fr) * 1999-05-27 2006-01-31 Acusphere, Inc. Matrices medicamenteuses poreuses et procedes de fabrication associes
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
EP1235598A2 (fr) 1999-11-12 2002-09-04 Angiotech Pharmaceuticals, Inc. Compositions et methodes destinees au traitement de maladies utilisant une therapie radioactive et des inhibiteurs du cycle cellulaire combines
SE515604C2 (sv) * 2000-04-28 2001-09-10 Bst Ab Förfarande och anordning för uppsugning och transport av vätskor, företrädesvis blod
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
JP2004529934A (ja) 2001-05-01 2004-09-30 アンジオテック ファーマシューティカルズ，インコーポレイテッド 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
DE60118983T3 (de) 2001-07-02 2016-07-07 Micro & Nano Materials Sagl Verfahren zur Herstellung von Nano- und Mikro-Teilchen
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
CA2461556A1 (fr) * 2001-10-15 2003-04-24 Crititech, Inc. Compositions et procedes destines a l'administration de microparticules de medicaments faiblement hydrosolubles et procedes de traitement associes
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
JP2003251127A (ja) * 2002-03-06 2003-09-09 Kazuo Hirakawa 集塵装置
DE60309300T3 (de) 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
EP1501483A2 (fr) * 2002-04-25 2005-02-02 Nektar Therapeutics UK Ltd Materiaux particulaires
AU2003231134A1 (en) 2002-04-26 2003-11-10 Teva Pharmaceutical Industries, Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
US9339459B2 (en) * 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (zh) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 紫杉醇纳米微粒的制备方法及应用
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US6916389B2 (en) * 2002-08-13 2005-07-12 Nanotechnologies, Inc. Process for mixing particulates
CN2578811Y (zh) * 2002-10-24 2003-10-08 陆纪清 全闭式煤粉取样装置
US20040220081A1 (en) * 2002-10-30 2004-11-04 Spherics, Inc. Nanoparticulate bioactive agents
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
JP4927535B2 (ja) 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
JP5645340B2 (ja) 2003-10-15 2014-12-24 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ 活性成分を含有するカチオンリポソームの投与方法
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US7208106B2 (en) 2003-10-24 2007-04-24 Ferro Corporation Method of forming particles
US7879360B2 (en) 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
DE10357091A1 (de) * 2003-12-06 2005-07-07 Degussa Ag Vorrichtung und Verfahren zur Abscheidung feinster Partikel aus der Gasphase
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
WO2006046670A1 (fr) 2004-10-29 2006-05-04 Nara Machinery Co., Ltd. Méthode de granulation de fines particules
WO2006068890A2 (fr) 2004-12-14 2006-06-29 Transave, Inc. Particules lipidiques comprenant des agents bioactifs, procedes de preparation et utilisation
ES2265262B1 (es) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20080003322A (ko) 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8118795B2 (en) * 2005-03-22 2012-02-21 Medindica-Pak, Inc Disposal chain supply systems method and apparatus
CN101160116B (zh) 2005-03-31 2011-12-07 利德斯公司 基于局部递送活性物质治疗前列腺疾病的方法
CN1923189A (zh) 2005-08-30 2007-03-07 孔庆忠 一种紫杉碱类抗癌药物的缓释注射剂
WO2007027941A2 (fr) 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue
KR20080077680A (ko) 2005-12-11 2008-08-25 에스씨에프 테크놀로지스 에이/에스 나노 크기 재료의 제조 방법
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101336899A (zh) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 含紫杉烷的抗癌缓释注射剂
DK1996160T3 (da) 2006-03-14 2010-07-05 Lidds Ab Bioresorberbar sammensætning med kontrolleret frigivelse
US7964029B2 (en) * 2006-07-17 2011-06-21 Thar Instrument, Inc. Process flowstream collection system
US7744923B2 (en) 2006-10-11 2010-06-29 Crititech, Inc. Method for precipitation of small medicament particles into use containers
WO2008044092A1 (fr) 2006-10-11 2008-04-17 Renault Trucks Camion doté d'un système d'accès passif sans clé
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
WO2009006590A2 (fr) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Procédés de préparation de docétaxel et de polymorphes
CN101129338A (zh) * 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
MX2010009670A (es) 2008-03-06 2010-09-22 Nitto Denko Corp Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
KR101242874B1 (ko) * 2008-03-24 2013-03-13 산요가세이고교 가부시키가이샤 수지 입자 및 그 제조 방법
JP5536654B2 (ja) 2008-09-19 2014-07-02 株式会社アクティバスファーマ 医療用複合有機化合物粉体、その製造方法ならびに懸濁液
CA2745238A1 (fr) 2008-12-02 2010-06-10 Biocompatibles Uk Limited Traitement de tumeur du pancreas
PT104693B (pt) 2009-07-27 2011-11-24 Univ Lisboa Nanopartículas lipídicas semi-sólidas contendo um agente antineoplásico e seu processo de preparação
AU2010289785A1 (en) 2009-08-24 2012-03-15 Baylor College Of Medicine Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
US20110209578A1 (en) * 2010-02-26 2011-09-01 Kuniaki Ara Nanoparticle manufacturing device and nanoparticle manufacturing method and method of manufacturing nanoparticle-dispersed liquid alkali metal
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
EP2575803B1 (fr) 2010-06-02 2017-07-26 Abraxis BioScience, LLC Procédé de traitement du cancer de la vessie
ES2776983T3 (es) 2010-09-21 2020-08-03 Cristal Delivery B V Moléculas enlazadoras biodegradables ajustables para la conjugación transitoria de componentes en sistemas de administración de fármacos, y sistemas de administración de fármacos preparados con ellas
US20150093440A1 (en) 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
EP2745921A3 (fr) * 2010-10-29 2014-10-01 Velico Medical, Inc. Système et Procédé de Séchage par Atomisation d'un Liquide
WO2012096995A2 (fr) * 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Dispositifs médicaux revêtus
PT2699233T (pt) 2011-04-20 2017-07-03 Univ Sydney Material particulado e toxina celular para utilização no tratamento de um tumor sólido
US20140154269A1 (en) 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
CN103764172A (zh) 2011-06-27 2014-04-30 科里斯塔鲁传送有限公司 控释系统
US11766459B2 (en) * 2011-07-08 2023-09-26 Jointechlabs, Inc. System and methods for preparation of adipose-derived stem cells
BR112014004590B1 (pt) * 2011-08-31 2019-11-19 Archer Daniels Midland Co processo para realizar uma oxidação em uma alimentação pulverizável
FR2980683B1 (fr) 2011-09-30 2014-11-21 Univ Paris Curie Dispositif de guidage d'un instrument medical insere dans une voie naturelle ou une voie artificielle d'un patient
CN102319898B (zh) * 2011-10-13 2013-05-08 西北工业大学 一种制备合金及金属基复合材料零部件的喷射成形系统
CN102488682A (zh) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 绿原酸的抗癌新用途
JP2013212494A (ja) * 2012-03-05 2013-10-17 Ricoh Co Ltd 樹脂微粒子の製造方法
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
CN102728414A (zh) 2012-07-07 2012-10-17 中山大学 用于制备单壁碳纳米管的催化剂的制备方法及其运用
TW201408304A (zh) 2012-08-31 2014-03-01 Cathay General Hospital 一種合併抗癌藥物及荷爾蒙之抗腎細胞癌藥物及其製造方法
CA2884707C (fr) 2012-09-21 2019-03-19 Lewis Bender Methode de traitement du cancer
US9132363B2 (en) * 2012-11-20 2015-09-15 Apeks Llc Extraction system
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2898408C (fr) 2013-02-28 2018-01-02 Pfizer Inc. Stabilite amelioree de compositions liquides nouvelles
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
US20140294967A1 (en) 2013-03-28 2014-10-02 Bbs Nanotechnology Llc. Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014169137A1 (fr) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Dispositifs et procédés d'administration de médicament locale pour traiter un cancer
CN203699094U (zh) * 2013-10-15 2014-07-09 雷海平 新式垃圾桶及配套内桶
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
CA2933883A1 (fr) 2013-12-17 2015-06-25 Genentech, Inc. Methodes de traitement de cancers her2 positifs au moyen d'antagonistes se liant a l'axe pd-1 et d'anticorps anti-her2
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
WO2015103005A1 (fr) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Composés amines amphiphiles et leur utilisation en tant qu'agents thérapeutiques et nanosupports
CN203737192U (zh) * 2014-01-20 2014-07-30 四川西汉电子科技有限责任公司 一种造粒机
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
US20150342872A1 (en) * 2014-06-01 2015-12-03 Crititech, Inc. Use of Paclitaxel Particles
CN203847940U (zh) 2014-06-04 2014-09-24 刘希 一种加料喷嘴调节支架
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US9533449B2 (en) * 2014-06-19 2017-01-03 Autodesk, Inc. Material deposition systems with four or more axes
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
KR102077518B1 (ko) * 2015-06-04 2020-02-14 크리티테크, 인크. 노즐 어셈블리 및 사용 방법
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
DE202016006620U1 (de) 2015-10-28 2017-04-12 Qass Gmbh Vorrichtungen zum Beobachten eines Magnetfelds eines Materialvolumens
KR20180096707A (ko) 2016-01-20 2018-08-29 페이트 세러퓨틱스, 인코포레이티드 입양 면역요법에서 면역 세포 조절을 위한 조성물 및 방법
EP3854381A1 (fr) * 2016-04-04 2021-07-28 Crititech, Inc. Formulations pour le traitement de tumeurs solides
CN107281502B (zh) 2016-04-05 2021-05-04 上海市肿瘤研究所 一种复合显影温敏凝胶栓塞剂、制备方法及其应用
WO2017178585A1 (fr) 2016-04-15 2017-10-19 Cellectis Méthode d'ingénierie par inactivation génique de cellules t spécifiquement hypersensibles à un médicament destinées à une utilisation en immunothérapie
US10160159B2 (en) * 2016-05-12 2018-12-25 Hewlett-Packard Development Company, L.P. Build material container
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018045239A1 (fr) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison et de porteuses pd-l1 pour le traitement de cancers
CA3056395C (fr) 2017-03-15 2022-06-28 Dfb Soria, Llc Therapie topique pour le traitement de malignites cutanees au moyen de nanoparticules de taxanes
WO2018170210A1 (fr) 2017-03-15 2018-09-20 Dfb Soria, Llc Thérapie topique pour le traitement de la néoplasie intraépithéliale vulvaire (vin) et des verrues génitales à l'aide de nanoparticules de taxanes
WO2018170207A1 (fr) 2017-03-15 2018-09-20 Dfb Soria, Llc Thérapie topique pour le traitement de kératoses cutanées à l'aide de nanoparticules de taxanes
CN110730679A (zh) 2017-06-09 2020-01-24 克里蒂泰克公司 囊内注射抗肿瘤颗粒治疗上皮囊肿
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック，インコーポレイテッド 肺障害の治療方法

Also Published As

Publication number Publication date
KR20180016366A (ko) 2018-02-14
JP2020203913A (ja) 2020-12-24
KR102317107B1 (ko) 2021-10-25
AU2016270558B2 (en) 2020-08-13
PT3302431T (pt) 2020-11-30
ES2833749T3 (es) 2021-06-15
US10993927B2 (en) 2021-05-04
HK1253021A1 (zh) 2019-06-06
US9814685B2 (en) 2017-11-14
US20180169058A1 (en) 2018-06-21
CA3026452C (fr) 2023-03-21
US20210000786A1 (en) 2021-01-07
EP3302423B1 (fr) 2022-05-25
JP6758325B2 (ja) 2020-09-23
US20160354336A1 (en) 2016-12-08
AU2016270549B2 (en) 2019-01-17
CA2988132A1 (fr) 2016-12-08
WO2016197091A1 (fr) 2016-12-08
HK1253020A1 (zh) 2019-06-06
EP3838264A1 (fr) 2021-06-23
CN114010628A (zh) 2022-02-08
EP3302780B1 (fr) 2019-04-17
CN107743418A (zh) 2018-02-27
EP3302780A1 (fr) 2018-04-11
RU2017140678A3 (fr) 2019-07-17
JP2022121532A (ja) 2022-08-19
JP6892394B2 (ja) 2021-06-23
CA2988132C (fr) 2021-04-27
KR102337080B1 (ko) 2021-12-08
US10751319B2 (en) 2020-08-25
US11123322B2 (en) 2021-09-21
WO2016197101A1 (fr) 2016-12-08
US20180116910A1 (en) 2018-05-03
KR20200020995A (ko) 2020-02-26
AU2016270559B2 (en) 2020-12-10
KR20180013906A (ko) 2018-02-07
KR102551708B1 (ko) 2023-07-06
AU2016270559A1 (en) 2017-11-16
US20160374953A1 (en) 2016-12-29
US10729673B2 (en) 2020-08-04
US20200101039A1 (en) 2020-04-02
WO2016197100A1 (fr) 2016-12-08
JP7096299B2 (ja) 2022-07-05
EP3302431B1 (fr) 2020-11-11
RU2017140678A (ru) 2019-07-09
JP2018524145A (ja) 2018-08-30
US10507195B2 (en) 2019-12-17
RU2750163C2 (ru) 2021-06-22
EP3302423A1 (fr) 2018-04-11
KR20180015635A (ko) 2018-02-13
CA3026454A1 (fr) 2016-12-08
CN107683131B (zh) 2021-09-28
HK1253021B (zh) 2020-01-24
KR102077518B1 (ko) 2020-02-14
AU2016270558A1 (en) 2017-11-16
KR20200134347A (ko) 2020-12-01
JP2018526188A (ja) 2018-09-13
BR112017025815A2 (pt) 2018-08-14
US20200405684A1 (en) 2020-12-31
SG10201913947RA (en) 2020-03-30
CA3026452A1 (fr) 2016-12-08
CN107683131A (zh) 2018-02-09
JP2018516907A (ja) 2018-06-28
US20210393569A1 (en) 2021-12-23
US11291646B2 (en) 2022-04-05
EP3302431A1 (fr) 2018-04-11
CN107683174A (zh) 2018-02-09
AU2016270549A1 (en) 2017-11-16
US20180125783A1 (en) 2018-05-10
US20200163928A1 (en) 2020-05-28
US9918957B2 (en) 2018-03-20
DK3302431T3 (da) 2020-11-30
JP6921759B2 (ja) 2021-08-18
HK1253018A1 (zh) 2019-06-06
CA3026454C (fr) 2023-07-04
US20170224650A1 (en) 2017-08-10
CN107683174B (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
HK1253018A1 (zh) 紫杉烷顆粒及其用途
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
GB201411197D0 (en) Composition and use thereof
PL3015526T3 (pl) Kompozycja na bazie wodorofluoroolefiny i jej zastosowanie
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
IL264813B (en) 2-oxo-imidazopyridines and their use
IL247315B (en) Anti-acth antibodies and their uses
HK1243077A1 (zh) 呱啶基吡唑並嘧啶酮及其用途
IL248424B (en) Neuroprotective substances and their uses
HK1247122A1 (zh) 組合及其用途
IL254241A0 (en) Etv2 and its uses
GB201517786D0 (en) Methods and materials
ZA201801211B (en) Cleaning particles and their use
GB201415409D0 (en) Particle counting and characterisation
GB201411196D0 (en) Composition and use thereof
GB2545167B (en) Cloches and use thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201514770D0 (en) Compounds and their use
GB201500278D0 (en) Novel combination and use